Tumor-Infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer

Journal of the National Cancer Institute

Volumn 108, Issue 8, 2016, Pages

  Rozek, Laura S ^a   Schmit, Stephanie L ^c   Greenson, Joel K ^a   Tomsho, Lynn P ^b   Rennert, Hedy S ^d   Rennert, Gad ^d   Gruber, Stephen B ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSE OF DEATH; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; ISRAEL; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; CELLULAR IMMUNITY; COLORECTAL TUMOR; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUSE OF DEATH; COLORECTAL NEOPLASMS; CROHN DISEASE; FEMALE; HUMANS; IMMUNITY, CELLULAR; ISRAEL; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84992378694     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw027     Document Type: Article

References (44)

1. Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359-E386.
2. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001; 10(9):917-923.
3. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001; 1(2):104-109.
4. Mei Z, Liu Y, Liu C, et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014; 110(6):1595-1605.
5. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012; 10:1.
6. Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000; 355(9217):1745-1750.
7. Jass JR Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50(1):113-130.
8. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population based study. Gastroenterology. 2007; 133(1):48-56.
9. Greenson JK, Bonner JD, Ben Yzhak O, et al. Pheno type of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol. 2003; 27(5):563-570.
10. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009; 33(1):126-133.
11. Rennert G LF, Rennert HS, Raskin L, Cohen I, Friedman V, et al. Molecularly driven survival patterns in colorectal cancer. Under review.
12. Drescher KM, Sharma P, Watson P, et al. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer. 2009; 8(3):231-239.
13. Banerjea A, Ahmed S, Hands RE, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer. 2004; 3:21.
14. Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001; 91(12):2417-2422.
15. Tougeron D, Fauquembergue E, Rouquette A, et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol. 2009; 22(9):1186-1195.
16. Svennevig JL, Lunde OC, Holter J, et al. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984; 49(3):375-377.
17. Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumourinfiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997; 182(3): 318-324.
18. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-1964.
19. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010; 222(4):350-366.
20. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; 15(20):6412-6420.
21. Vayrynen JP, Sajanti SA, Klintrup K, et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer. 2014; 134(9):2126-2135.
22. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1990; 3(3):332-335.
23. Harrison JC, Dean PJ, el-Zeky F, et al. Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum Pathol. 1995; 26(1):31-38.
24. Chang EY, Dorsey PB, Frankhouse J, et al. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. Arch Surg. 2009; 144(6):511-515.
25. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352(21):2184-2192.
26. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986; 10(5):437-459.
27. Raskin L, Dakubo JC, Palaski N, et al. Distinct molecular features of colorectal cancer in Ghana. Cancer Epidemiol. 2013; 37(5):556-561.
28. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011; 71(7):2632-2642.
29. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81:515-526.
30. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015; 107(3): dju427.
31. Takemoto N, Konishi F, Yamashita K, et al. The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol. 2004; 34(2):90-98.
32. Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999; 154(6): 1805-1813.
33. Bernal M, Concha A, Saenz-Lopez P, et al. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol Immunother. 2011; 60(6):869-882.
34. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001; 158(2):527-535.
35. Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg. 2004; 91(4):469-475.
36. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumourinfiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011; 105(1):93-103.
37. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009; 9(7):489-499.
38. Phipps AI, Limburg PJ, Baron JA, et al. Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology. 2014; 148(1):77-87.
39. Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013; 119(8):1528-1536.
40. Parajuli R, Bjerkaas E, Tverdal A, et al. Cigarette smoking and colorectal cancer mortality among 602,242 Norwegian males and females. Clin Epidemiol. 2014; 6:137-145.
41. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009; 302(6):649-658.
42. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012; 367(17):1596-1606.
43. Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012; 131(3):752-759.
44. HH Y, Q S, SR A, et al. Racial Differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). In. American Society of Clinical Oncology Annual Meeting. Chicago, IL; 2014.